885271-63-6 Usage
General Description
Methyl-3-bromoindazole-4-carboxylate is a chemical compound with the molecular formula C9H7BrN2O2. It is used as a building block in the synthesis of various pharmaceutical and agrochemical compounds. METHYL-3-BROMOINDAZOLE-4-CARBOXYLATE is a derivative of indazole, a five-membered aromatic heterocyclic compound. It is commonly used as a synthetic intermediate in the production of pharmaceuticals, including nonsteroidal anti-inflammatory drugs and antibacterial agents. The presence of the bromine atom in the structure makes it a valuable precursor in organic synthesis and medicinal chemistry. Methyl-3-bromoindazole-4-carboxylate has promising potential for use in the pharmaceutical industry due to its versatile applications in drug discovery and development.
Check Digit Verification of cas no
The CAS Registry Mumber 885271-63-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,8,5,2,7 and 1 respectively; the second part has 2 digits, 6 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 885271-63:
(8*8)+(7*8)+(6*5)+(5*2)+(4*7)+(3*1)+(2*6)+(1*3)=206
206 % 10 = 6
So 885271-63-6 is a valid CAS Registry Number.
InChI:InChI=1/C9H7BrN2O2/c1-14-9(13)5-3-2-4-6-7(5)8(10)12-11-6/h2-4H,1H3,(H,11,12)
885271-63-6Relevant articles and documents
Azacycle diketone compound and preparation method thereof (by machine translation)
-
, (2020/09/12)
The invention provides a azacyclodiketone compound which is characterized by being a compound represented by the following structure. The compound has inhibitory activity on cap-dependent endonuclease. (by machine translation)
INDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS
-
, (2009/12/05)
Disclosed indazoles compounds that are useful as antagonists of CCR1 activity and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
